Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
7.94M
-
Number of holders
-
97
-
Total 13F shares, excl. options
-
103M
-
Shares change
-
+5.46M
-
Total reported value, excl. options
-
$143M
-
Value change
-
+$8.94M
-
Put/Call ratio
-
1.41
-
Number of buys
-
37
-
Number of sells
-
-31
-
Price
-
$1.39
Significant Holders of X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share (XFOR) as of Q1 2024
110 filings reported holding XFOR - X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share as of Q1 2024.
X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share (XFOR) has 97 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 103M shares
.
Largest 10 shareholders include Bain Capital Life Sciences Investors, LLC (16.9M shares), NEA Management Company, LLC (15M shares), BlackRock Inc. (8.74M shares), VANGUARD GROUP INC (7.83M shares), ORBIMED ADVISORS LLC (7.13M shares), Soleus Capital Management, L.P. (4.58M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (4.28M shares), Sio Capital Management, LLC (3.59M shares), PERCEPTIVE ADVISORS LLC (3.55M shares), and KINGDON CAPITAL MANAGEMENT, L.L.C. (3.47M shares).
This table shows the top 97 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.